Cancer and "Diet Myths": Beware of Pseudoscience in the Social Media Era

Updated on: July 06,2024 0

Cancer and "Diet Myths": Beware of Pseudoscience in the Social Media Era

Updated on:July 06,2024 0

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa

Updated on: October 11,2023 205

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa

Updated on:October 11,2023 205

Study ties diabetes and obesity to increased risk of liver cancer relapse

byOsaka Metropolitan UniversityDiabetes mellitus and obesity are risks for late postoperative recurrence of hepatocellular carcinoma. Credit: Osaka Metropolitan UniversityHepatocellular carcinom

Updated on: October 24,2024 0

Study ties diabetes and obesity to increased risk of liver cancer relapse

byOsaka Metropolitan UniversityDiabetes mellitus and obesity are risks for late postoperative recurrence of hepatocellular carcinoma. Credit: Osaka Metropolitan UniversityHepatocellular carcinom

Updated on:October 24,2024 0

CHMP Recommends Against Renewal of Marketing Authorization for Belantamab Mafodotin in R/R Myeloma

September 18, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against renewal of the conditional marketing authorization for belantamab maf

Updated on: October 24,2023 77

CHMP Recommends Against Renewal of Marketing Authorization for Belantamab Mafodotin in R/R Myeloma

September 18, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against renewal of the conditional marketing authorization for belantamab maf

Updated on:October 24,2023 77

Using mathematical modeling and dynamic biomarkers to characterize metastatic disease during adaptive therapy

byH. Lee Moffitt Cancer Center & Research InstituteMathematical model overview and design. A, Simulated treatment trajectory. During the seeding/growth phase, metastases are seeded and grown

Updated on: January 04,2024 8

Using mathematical modeling and dynamic biomarkers to characterize metastatic disease during adaptive therapy

byH. Lee Moffitt Cancer Center & Research InstituteMathematical model overview and design. A, Simulated treatment trajectory. During the seeding/growth phase, metastases are seeded and grown

Updated on:January 04,2024 8

New epigenetic markers for prostate cancer discovered

byGarvan Institute of Medical ResearchHistopathological image of a high grade prostate cancer. Credit: Prof James KenchNew epigenetic biomarkers to predict more aggressive forms of prostate canc

Updated on: December 21,2023 10

New epigenetic markers for prostate cancer discovered

byGarvan Institute of Medical ResearchHistopathological image of a high grade prostate cancer. Credit: Prof James KenchNew epigenetic biomarkers to predict more aggressive forms of prostate canc

Updated on:December 21,2023 10

Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia

September 5, 2023Kristi RosaThe National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma w

Updated on: October 12,2023 87

Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia

September 5, 2023Kristi RosaThe National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma w

Updated on:October 12,2023 87

Study reveals promising therapeutic approach for prostate cancer bone metastasis

by TranSpreadMiR-18a-5p was overexpressed in osteoblastic lesions of PCa bone metastasis. (A–D) Bone specimens of PCa patients with bone metastasis. (A) Immunohistochemical labeling of PSA (brown repr

Updated on: October 14,2023 270

Study reveals promising therapeutic approach for prostate cancer bone metastasis

by TranSpreadMiR-18a-5p was overexpressed in osteoblastic lesions of PCa bone metastasis. (A–D) Bone specimens of PCa patients with bone metastasis. (A) Immunohistochemical labeling of PSA (brown repr

Updated on:October 14,2023 270

Novel risk score for cardiovascular complications after bone marrow transplant

by Noah Fromson,University of Michigan3D Model of the heart by Dr. Matthew Bramlet. Credit: NIHFor thousands of Americans each year, a bone marrow transplant has the potential to cure diseases s

Updated on: March 20,2024 12

Novel risk score for cardiovascular complications after bone marrow transplant

by Noah Fromson,University of Michigan3D Model of the heart by Dr. Matthew Bramlet. Credit: NIHFor thousands of Americans each year, a bone marrow transplant has the potential to cure diseases s

Updated on:March 20,2024 12

Q and A: Is surgery best for an acoustic neuroma?

by Joseph BreenCredit: Pixabay/CC0 Public DomainI was diagnosed with an acoustic neuroma last year after I went to the doctor due to more frequent headaches. I read that surgery often is needed for th

Updated on: January 10,2024 12

Q and A: Is surgery best for an acoustic neuroma?

by Joseph BreenCredit: Pixabay/CC0 Public DomainI was diagnosed with an acoustic neuroma last year after I went to the doctor due to more frequent headaches. I read that surgery often is needed for th

Updated on:January 10,2024 12

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

August 17, 2023Chris RyanThe European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refract

Updated on: October 12,2023 6

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

August 17, 2023Chris RyanThe European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refract

Updated on:October 12,2023 6

Progression-free survival increased with zanubrutinib in leukemia

by Elana Gotkine HealthDay ReporterProgression-free survival is significantly longer with zanubrutinib than ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or s

Updated on: December 19,2023 12

Progression-free survival increased with zanubrutinib in leukemia

by Elana Gotkine HealthDay ReporterProgression-free survival is significantly longer with zanubrutinib than ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or s

Updated on:December 19,2023 12